Randomized Trialhigh evidence
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England)·October 4, 2025·PMID 40975112
Why it mattersYouth-onset type 2 diabetes is often harder to control than adult-onset disease and has limited treatment options. This trial provides high-level evidence that tirzepatide can substantially improve glycaemia and weight-related measures in this population, with a safety profile similar to that seen in adults.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled